KBC Group NV Acquires Shares of 655 Amedisys, Inc. (NASDAQ:AMED)

KBC Group NV acquired a new position in shares of Amedisys, Inc. (NASDAQ:AMED) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 655 shares of the health services provider’s stock, valued at approximately $63,000.

Several other institutional investors have also recently made changes to their positions in AMED. Innealta Capital LLC purchased a new position in Amedisys during the second quarter worth about $64,000. Signaturefd LLC boosted its stake in shares of Amedisys by 88.2% in the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock worth $104,000 after buying an additional 530 shares during the last quarter. CWM LLC grew its holdings in shares of Amedisys by 14.5% in the third quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock valued at $211,000 after acquiring an additional 277 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new stake in shares of Amedisys during the third quarter valued at approximately $243,000. Finally, GAM Holding AG bought a new stake in Amedisys during the second quarter worth $275,000. Institutional investors own 94.36% of the company’s stock.

Amedisys Trading Up 0.5 %

NASDAQ:AMED opened at $90.64 on Friday. Amedisys, Inc. has a 12 month low of $88.81 and a 12 month high of $98.95. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average is $95.34 and its 200 day moving average is $95.75. The stock has a market capitalization of $2.97 billion, a PE ratio of 35.97, a price-to-earnings-growth ratio of 1.89 and a beta of 0.78.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.19). The firm had revenue of $587.67 million during the quarter, compared to the consensus estimate of $586.75 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.98 earnings per share. Sell-side analysts expect that Amedisys, Inc. will post 4.55 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft downgraded Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price objective for the company. in a research note on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $100.67.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.